PIK3CA and breast cancer: The addition of ipatasertib to standard first-line maintenance with trastuzumab and pertuzumab (after a taxane-based chemotherapy) is under investigation in a single arm phase Ib trial (SOLTI-1507/IPATHER) in patients with HER2+/PIK3CA-mutated advanced BC.